Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 12/20 | 0.46 |
| ▸ | CCKAR | P32238 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 5/20 | 0.44 |
| ▸ | CPA1 | P15085 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24435832 | 0.96 | ACE (0.48) | RENACECCKARCCKBROPRD1 | |
| SCHEMBL22457528 | 0.96 | ACE (0.49) | RENACEMMECPA1ACE2 | |
| SCHEMBL24435980 | 0.96 | ACE (0.49) | RENACEMMECPA1ACE2 | |
| SCHEMBL24435839 | 0.91 | CTSS (0.51) | ACEMMECTSSCTSK | |
| SCHEMBL22457554 | 0.91 | REN (0.51) | RENACEMMECPA1ACE2 | |
| SCHEMBL22457519 | 0.89 | REN (0.55) | RENACEMMECPA1ACE2 | |
| SCHEMBL15566416 | 0.85 | ACE (0.52) | ACEMMECPA1ACE2CTSS | |
| SCHEMBL19474651 | 0.85 | ACE (0.52) | ACEMMECPA1ACE2CTSS | |
| SCHEMBL15566419 | 0.85 | ACE (0.52) | ACEMMECPA1ACE2CTSS | |
| SCHEMBL22457492 | 0.85 | REN (0.58) | RENACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NGLY1, NPPA, NPEPPS | REN 1579/4885ACE 982/4885CCKAR 1512/4885 |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NGLY1, NPPA, NPEPPS | REN 1579/4885ACE 982/4885CCKAR 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.